Exemestane vs Letrozole

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HR+/HER2- Metastatic Breast Cancer

Shared mechanism: Aromatase · full HR+/HER2- Metastatic Breast Cancer pipeline

Exemestane

Marketed by Pfizer

Approved in HR+/HER2- Metastatic Breast Cancersmall molecule
Partial signal

NCT00002777 · Phase 3 · completed

The study used randomization and an active tamoxifen comparator with an estimated sample size of 342 participants. The registry record gives no statistical test for the primary comparison; the key result shown reports it from the cited source. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Next expected readout: December 2026 · NCT07163481 (registry estimate)

Reported efficacy

Objective response rate: 46% exemestane vs 31% tamoxifen (odds ratio 1.85, 95% CI 1.21-2.82, P=.005). Median progression-free survival (the trial's primary endpoint): 9.9 months exemestane vs 5.8 months tamoxifen; long-term log-rank P=.121 (not statistically significant). (missed)

Result source: NCT00002777

Letrozole

Marketed by Novartis

Approved in HR+/HER2- Metastatic Breast Cancersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT06974929 (registry estimate)

Reported efficacy

Disease-free survival (5 years): Estimated 4-year disease-free survival: letrozole 93% vs placebo 87% (75 vs 132 recurrences/new cancers out of 5187 enrolled); P<=0.001 (met)

Result source: NCT00003140

Results for HR+/HER2- Metastatic Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointExemestaneLetrozole
PFS, median7.3 vs 10vs Capecitabinen 153NCT02028507
14 other results
20.2 vs 15.6vs Endocrine Therapyn 173NCT00601900
17 other results
OS, median33.7 vs 32vs Capecitabinen 206NCT02028507
7 other results
47.2 vs 43.9vs Endocrine Therapyn 173NCT00601900
7 other results
ORR14.3%bwk 48 · n 49NCT01743560
6 other results
  • 6.1% vs 0% n 49 · Phase 2 · secondary NCT00767520
  • 5.8% vs 6.3% wk 104 · n 52 · Phase 2 · secondary NCT01381874
  • 12.1% vs 6.3% wk 104 · n 66 · Phase 2 · secondary NCT01381874
  • 7% 4 mg + Exemestane · n 43 · Phase 2 · secondary NCT02049957
  • 0% 4 mg + Exemestane · n 35 · Phase 2 · secondary NCT02049957
  • 8.3% n 36 · Phase 2 · secondary NCT00810797
29.3%bn 3246NCT02941926
8 other results
Clinical benefit rate48.2%bn 199NCT03176238
10 other results
  • 30.6% n 36 · Phase 3 · secondary NCT03176238
  • 44% 4 mg + Exemestane · wk 16 · n 43 · Phase 2 · primary NCT02049957
  • 23% 4 mg + Exemestane · wk 16 · n 35 · Phase 2 · primary NCT02049957
  • 30.6% vs 12.2% wk 24 · n 49 · Phase 2 · secondary NCT00767520
  • 9.6% vs 12.7% wk 104 · n 52 · Phase 2 · secondary NCT01381874
  • 22.7% vs 12.7% wk 104 · n 66 · Phase 2 · secondary NCT01381874
  • 28% 4 mg + Exemestane · wk 24 · n 43 · Phase 2 · secondary NCT02049957
  • 23% 4 mg + Exemestane · wk 24 · n 35 · Phase 2 · secondary NCT02049957
  • 50% n 10 · Phase 2 · secondary NCT02648477
  • 20% n 20 · Phase 2 · secondary NCT02648477
70.7%bn 3246NCT02941926
6 other results

PFS, median

Exemestane
7.3 vs 10vs Capecitabinen 153NCT02028507
14 other results
Letrozole
20.2 vs 15.6vs Endocrine Therapyn 173NCT00601900
17 other results

OS, median

Exemestane
33.7 vs 32vs Capecitabinen 206NCT02028507
7 other results
Letrozole
47.2 vs 43.9vs Endocrine Therapyn 173NCT00601900
7 other results

ORR

Exemestane
14.3%bwk 48 · n 49NCT01743560
6 other results
  • 6.1% vs 0% n 49 · Phase 2 · secondary NCT00767520
  • 5.8% vs 6.3% wk 104 · n 52 · Phase 2 · secondary NCT01381874
  • 12.1% vs 6.3% wk 104 · n 66 · Phase 2 · secondary NCT01381874
  • 7% 4 mg + Exemestane · n 43 · Phase 2 · secondary NCT02049957
  • 0% 4 mg + Exemestane · n 35 · Phase 2 · secondary NCT02049957
  • 8.3% n 36 · Phase 2 · secondary NCT00810797
Letrozole
29.3%bn 3246NCT02941926
8 other results

Clinical benefit rate

Exemestane
48.2%bn 199NCT03176238
10 other results
  • 30.6% n 36 · Phase 3 · secondary NCT03176238
  • 44% 4 mg + Exemestane · wk 16 · n 43 · Phase 2 · primary NCT02049957
  • 23% 4 mg + Exemestane · wk 16 · n 35 · Phase 2 · primary NCT02049957
  • 30.6% vs 12.2% wk 24 · n 49 · Phase 2 · secondary NCT00767520
  • 9.6% vs 12.7% wk 104 · n 52 · Phase 2 · secondary NCT01381874
  • 22.7% vs 12.7% wk 104 · n 66 · Phase 2 · secondary NCT01381874
  • 28% 4 mg + Exemestane · wk 24 · n 43 · Phase 2 · secondary NCT02049957
  • 23% 4 mg + Exemestane · wk 24 · n 35 · Phase 2 · secondary NCT02049957
  • 50% n 10 · Phase 2 · secondary NCT02648477
  • 20% n 20 · Phase 2 · secondary NCT02648477
Letrozole
70.7%bn 3246NCT02941926
6 other results
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
11 other shared endpoints and safety

Coverage. Exemestane: 15 of 15 rows · Letrozole: 15 of 15 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricExemestane
Rows use multiple source trials
Letrozole
Rows use multiple source trials
Clinical Benefit
event count · % of participants
No placebo or comparator arm
23.8% (n=239)*a,b,c,d
NCT00253422 · Phase 3 · registry result, not featured evidence · converted to % from 57 Participants as posted
70.7% (n=188)*600 mge,a,b,c,d
NCT03822468 · Phase 2 · registry result, not featured evidence · converted to % from 133 Participants as posted
show 1 more dose
75.5% (n=188)*400 mg
NCT03822468 · Phase 2 · registry result, not featured evidence · converted to % from 142 Participants as posted
Clinical Benefit
responder rate · % of participants
No placebo or comparator arm
48.2% (n=199)e,f,d
NCT03176238 · Phase 3 · registry result, not featured evidence · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more dose
30.6% (n=36)
NCT03176238 · Phase 3 · registry result, not featured evidence · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
70.7% (n=3246)f,d
NCT02941926 · Phase 3 · registry result, not featured evidence · combination
5 other source trials
46.2% (n=119)
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
35.1% (n=114)
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
38.3% (n=115)
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
50% (n=10)
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
20% (n=20)
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
Duration of Response
time to event · months
No placebo or comparator arm
12.8 monthsa,b,c,d
NCT00253422 · Phase 3 · registry result, not featured evidence
13.8 monthse,a,b,c,d
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
show 2 more doses
6.5 months
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
16.5 months
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
ORR
responder rate · % of participants
No placebo or comparator arm
14.3% (n=49) @ 48wkg,b,d
NCT01743560 · Phase 4 · registry result, not featured evidence · combination
3 other source trials
8.3% (n=36)
NCT00810797 · Phase 2 · registry result, not featured evidence
0% (n=35)4 mg + Exemestane
NCT02049957 · Phase 2 · registry result, not featured evidence · combination
7% (n=43)4 mg + Exemestane
NCT02049957 · Phase 2 · registry result, not featured evidence · combination
29.3% (n=3246)g,b,d
NCT02941926 · Phase 3 · registry result, not featured evidence · combination
7 other source trials
19.3% (n=119)
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
17.5% (n=114)
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
25.2% (n=115)
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
41.5% (n=188)400 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
45.3% (n=188)600 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
47.6% (n=42)125 mg + 2.5 mg
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
37.2% (n=43)
NCT01231659 · Phase 2 · registry result, not featured evidence · combination
ORR
event count · % of participants
No placebo or comparator arm
4.2% (n=239)*a,b,c,d
NCT00253422 · Phase 3 · registry result, not featured evidence · converted to % from 10 Participants as posted
2 other source trials
50% (n=10)*
NCT02648477 · Phase 2 · registry result, not featured evidence · combination · converted to % from 5 Participants as posted
10% (n=20)*
NCT02648477 · Phase 2 · registry result, not featured evidence · combination · converted to % from 2 Participants as posted
50% (n=10)*e,a,b,c,d
NCT02648477 · Phase 2 · registry result, not featured evidence · combination · converted to % from 5 Participants as posted
show 1 more dose
10% (n=20)*
NCT02648477 · Phase 2 · registry result, not featured evidence · combination · converted to % from 2 Participants as posted
Overall Survival
responder rate · % of participants
No placebo or comparator arm
74.2% (n=49) @ 48wkg,b
NCT01743560 · Phase 4 · registry result, not featured evidence · combination
93.3% (n=307) @ 48wke,g,b
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
show 2 more doses
87.5% (n=26) @ 48wk
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
86.1% (n=154) @ 48wk
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
Overall Survival
time to event · months
No placebo or comparator arm
22.5 monthsb,c,d
NCT00253422 · Phase 3 · registry result, not featured evidence
4 other source trials
15.6 months
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
17.2 months
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
14 months4 mg + Exemestane
NCT02049957 · Phase 2 · registry result, not featured evidence · combination
15.9 months4 mg + Exemestane
NCT02049957 · Phase 2 · registry result, not featured evidence · combination
NA monthse,b,c,d
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
show 2 more doses
NA months
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
NA months
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
PFS
time to event · months
No placebo or comparator arm
5.45 months @ 48wk*g,b,d
NCT01743560 · Phase 4 · registry result, not featured evidence · combination · converted to months from 23.6 weeks as posted
8 other source trials
3.5 months
NCT00253422 · Phase 3 · registry result, not featured evidence
9.37 months*
NCT03176238 · Phase 3 · registry result, not featured evidence · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 · converted to months from 40.6 weeks as posted
8.54 months*
NCT03176238 · Phase 3 · registry result, not featured evidence · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 · converted to months from 37 weeks as posted
5.2 months
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
1.8 months
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
4.3 months
NCT00810797 · Phase 2 · registry result, not featured evidence
3.3 months4 mg + Exemestane
NCT02049957 · Phase 2 · registry result, not featured evidence · combination
4.1 months4 mg + Exemestane
NCT02049957 · Phase 2 · registry result, not featured evidence · combination
21.8 monthse,g,b,d
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
show 2 more doses
16.5 months
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
8.8 months
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
PFS
responder rate · % of participants
No placebo or comparator arm
18.4% (n=49) @ 48wkg,b
NCT01743560 · Phase 4 · registry result, not featured evidence · combination
61.9% (n=307) @ 48wke,g,b
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
show 2 more doses
58.7% (n=26) @ 48wk
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
47.5% (n=154) @ 48wk
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
Time to Progression
time to event · months
No placebo or comparator arm
6.9 monthsh,b,d
NCT00201864 · Phase 2 · registry result, not featured evidence · combination
27.1 monthsh,b,d
NCT02941926 · Phase 3 · registry result, not featured evidence · combination
Time to Treatment Failure
time to event · months
No placebo or comparator arm
3.4 monthsa,b,c,d
NCT00253422 · Phase 3 · registry result, not featured evidence
2 other source trials
1.85 months*
NCT01870505 · Phase 1 · registry result, not featured evidence · combination · converted to months from 8 weeks as posted
3.92 months*
NCT01870505 · Phase 1 · registry result, not featured evidence · combination · converted to months from 17 weeks as posted
14.78 months*a,b,c,d
NCT03633331 · Phase 2 · registry result, not featured evidence · combination · converted to months from 450 days as posted
Dropout rate
29.6%i
NCT01176916 · Phase 4 · registry result, not featured evidence
show 40 more results
—Everolimus + Exemestane
NCT01743560 · Phase 4 · registry result, not featured evidence · combination
82.7%Everolimus and Exemestane
NCT01743560 · Phase 4 · registry result, not featured evidence · combination
0.4%
NCT00253422 · Phase 3 · registry result, not featured evidence
n/a: no completion milestone
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestoneAsian Everolimus + Exemestane
NCT03176238 · Phase 3 · registry result, not featured evidence · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
n/a: no completion milestoneNon-Asian Everolimus + Exemestane
NCT03176238 · Phase 3 · registry result, not featured evidence · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
0%
NCT00083174 · Phase 3 · registry result, not featured evidence
0.1%
NCT00036270 · Phase 3 · registry result, not featured evidence
0%Cohort 1 (Pembrolizumab, Doxorubic
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
0%Cohort 2 (Pembrolizumab, Anti-estr
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT02258451 · Phase 2 · registry result, not featured evidence · combination
0%
NCT00810797 · Phase 2 · registry result, not featured evidence
71.7%Abiraterone Acetate + Exemestane +
NCT01381874 · Phase 2 · registry result, not featured evidence · combination
70.8%Abiraterone Acetate + Prednisone
NCT01381874 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone5 mg + Exemestane
NCT02049957 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone4 mg + Exemestane
NCT02049957 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone4 mg + Exemestane
NCT02049957 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone4 mg + Exemestane
NCT02049957 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone3 mg + Exemestane
NCT02049957 · Phase 2 · registry result, not featured evidence · combination
0%
NCT00201864 · Phase 2 · registry result, not featured evidence · combination
13.9%
NCT00767520 · Phase 2 · registry result, not featured evidence · combination
8.7%
NCT00073073 · Phase 2 · registry result, not featured evidence
—
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
—125mg
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
—100mg
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
—100mg
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
91.7%80mg bd 1w/1w + Ex 25mg
NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination
—80mg bd 2w/1w + Ex 25mg
NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination
100%80mg bd Cont + Ex 25mg
NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination
100%40mg Cont + Ex 25mg
NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination
—40mg bd Cont + Ex 25mg
NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination
100%Part B: AZD4547 + Fulvestrant
NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination
0%DOSE FINDING PHASE, Arm A, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
0%DOSE FINDING PHASE, Arm A, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
0%DOSE FINDING PHASE, Arm B, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
0%Dose Finding Phase, Arm C, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
0%Dose Finding Phase, Arm C, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
0%Dose Finding Phase, Arm D, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
0%Dose Finding Phase, Arm D, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
0%Dose Finding Phase, Arm D, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
0%Fixed Dose Letrozolej
NCT01035099 · Phase 4 · registry result, not featured evidence
show 47 more results
0%Titrated Dose Letrozole
NCT01035099 · Phase 4 · registry result, not featured evidence
69.1%Palbociclib+Letrozole Australia Co
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
34%Palbociclib+Letrozole India Cohort
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
0%
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
59.9%
NCT02941926 · Phase 3 · registry result, not featured evidence · combination
68.7%Ribociclib + Letrozole Cohort A
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
—Ribociclib + Letrozole Cohort B
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
76.9%Ribociclib + Letrozole Cohort B1
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
87.9%Ribociclib + Letrozole Cohort B2
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT02600923 · Phase 3 · registry result, not featured evidence · combination
0%
NCT00754845 · Phase 3 · registry result, not featured evidence
1.1%
NCT03633331 · Phase 2 · registry result, not featured evidence · combination
99.2%Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
100%Cohort B: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort B: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
92.1%Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone600 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
—600mg
NCT03822468 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone400 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
—400mg
NCT03822468 · Phase 2 · registry result, not featured evidence
0%Cohort 1 (Pembrolizumab, Doxorubic
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
0%Cohort 2 (Pembrolizumab, Anti-estr
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
68.8%600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
—600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
1.4%
NCT03644186 · Phase 2 · registry result, not featured evidence · combination
1.8%
NCT03007979 · Phase 2 · registry result, not featured evidence · combination
0%
NCT00530868 · Phase 2 · registry result, not featured evidence · combination
—125 mg + 2.5 mg
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
—125 mg + 2.5 mg
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
—2.5 mg daily
NCT00579826 · Phase 2 · registry result, not featured evidence
17.2%Letrozole
NCT00579826 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone
NCT01231659 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT00696072 · Phase 2 · registry result, not featured evidence · combination
12.1%
NCT00090857 · Phase 2 · registry result, not featured evidence
12.5%
NCT00867217 · Phase 2 · registry result, not featured evidence
12.5%
NCT01129622 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone50 mg with letrozole
NCT00708214 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone40 mg with letrozole
NCT00708214 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone30 mg with letrozole
NCT00708214 · Phase 2 · registry result, not featured evidence · combination
100%75 mg intermittent
NCT00062751 · Phase 2 · registry result, not featured evidence · combination
100%30 mg intermittent
NCT00062751 · Phase 2 · registry result, not featured evidence · combination
83.3%25 mg daily
NCT00062751 · Phase 2 · registry result, not featured evidence · combination
100%10 mg daily
NCT00062751 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs
10.8%i
NCT01176916 · Phase 4 · registry result, not featured evidence
show 40 more results
—Everolimus + Exemestane
NCT01743560 · Phase 4 · registry result, not featured evidence · combination
15.4%Everolimus and Exemestane
NCT01743560 · Phase 4 · registry result, not featured evidence · combination
—
NCT00253422 · Phase 3 · registry result, not featured evidence
5.2%
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
—Asian Everolimus + Exemestane
NCT03176238 · Phase 3 · registry result, not featured evidence · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
—Non-Asian Everolimus + Exemestane
NCT03176238 · Phase 3 · registry result, not featured evidence · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
—
NCT00083174 · Phase 3 · registry result, not featured evidence
—
NCT00036270 · Phase 3 · registry result, not featured evidence
—Cohort 1 (Pembrolizumab, Doxorubic
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
—Cohort 2 (Pembrolizumab, Anti-estr
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
11.3%
NCT02258451 · Phase 2 · registry result, not featured evidence · combination
—
NCT00810797 · Phase 2 · registry result, not featured evidence
—Abiraterone Acetate + Exemestane +
NCT01381874 · Phase 2 · registry result, not featured evidence · combination
—Abiraterone Acetate + Prednisone
NCT01381874 · Phase 2 · registry result, not featured evidence · combination
16.7%5 mg + Exemestane
NCT02049957 · Phase 2 · registry result, not featured evidence · combination
0%4 mg + Exemestane
NCT02049957 · Phase 2 · registry result, not featured evidence · combination
17.1%4 mg + Exemestane
NCT02049957 · Phase 2 · registry result, not featured evidence · combination
11.6%4 mg + Exemestane
NCT02049957 · Phase 2 · registry result, not featured evidence · combination
33.3%3 mg + Exemestane
NCT02049957 · Phase 2 · registry result, not featured evidence · combination
—
NCT00201864 · Phase 2 · registry result, not featured evidence · combination
—
NCT00767520 · Phase 2 · registry result, not featured evidence · combination
—
NCT00073073 · Phase 2 · registry result, not featured evidence
—
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
—125mg
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
—100mg
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
—100mg
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
33.3%80mg bd 1w/1w + Ex 25mg
NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination
—80mg bd 2w/1w + Ex 25mg
NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination
40%80mg bd Cont + Ex 25mg
NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination
20%40mg Cont + Ex 25mg
NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination
—40mg bd Cont + Ex 25mg
NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination
0%Part B: AZD4547 + Fulvestrant
NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination
—DOSE FINDING PHASE, Arm A, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
—DOSE FINDING PHASE, Arm A, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
—DOSE FINDING PHASE, Arm B, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
—Dose Finding Phase, Arm C, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
—Dose Finding Phase, Arm C, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
—Dose Finding Phase, Arm D, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
—Dose Finding Phase, Arm D, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
—Dose Finding Phase, Arm D, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
—Fixed Dose Letrozolej
NCT01035099 · Phase 4 · registry result, not featured evidence
show 47 more results
—Titrated Dose Letrozole
NCT01035099 · Phase 4 · registry result, not featured evidence
3.9%Palbociclib+Letrozole Australia Co
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
2%Palbociclib+Letrozole India Cohort
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
—
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
15.5%
NCT02941926 · Phase 3 · registry result, not featured evidence · combination
22.6%Ribociclib + Letrozole Cohort A
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
—Ribociclib + Letrozole Cohort B
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
23.1%Ribociclib + Letrozole Cohort B1
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
17.8%Ribociclib + Letrozole Cohort B2
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
2.3%
NCT02600923 · Phase 3 · registry result, not featured evidence · combination
—
NCT00754845 · Phase 3 · registry result, not featured evidence
—
NCT03633331 · Phase 2 · registry result, not featured evidence · combination
15.7%Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
11.1%Cohort B: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort B: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
10.3%Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
12.8%600 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
—600mg
NCT03822468 · Phase 2 · registry result, not featured evidence
11.2%400 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
—400mg
NCT03822468 · Phase 2 · registry result, not featured evidence
—Cohort 1 (Pembrolizumab, Doxorubic
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
—Cohort 2 (Pembrolizumab, Anti-estr
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
7.1%600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
—600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
—
NCT03644186 · Phase 2 · registry result, not featured evidence · combination
—
NCT03007979 · Phase 2 · registry result, not featured evidence · combination
—
NCT00530868 · Phase 2 · registry result, not featured evidence · combination
—125 mg + 2.5 mg
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
—125 mg + 2.5 mg
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
—2.5 mg daily
NCT00579826 · Phase 2 · registry result, not featured evidence
—Letrozole
NCT00579826 · Phase 2 · registry result, not featured evidence
12.5%
NCT01231659 · Phase 2 · registry result, not featured evidence · combination
17.5%
NCT00696072 · Phase 2 · registry result, not featured evidence · combination
6.1%
NCT00090857 · Phase 2 · registry result, not featured evidence
—
NCT00867217 · Phase 2 · registry result, not featured evidence
—
NCT01129622 · Phase 2 · registry result, not featured evidence
42.9%50 mg with letrozole
NCT00708214 · Phase 2 · registry result, not featured evidence · combination
46.2%40 mg with letrozole
NCT00708214 · Phase 2 · registry result, not featured evidence · combination
25%30 mg with letrozole
NCT00708214 · Phase 2 · registry result, not featured evidence · combination
33.3%75 mg intermittent
NCT00062751 · Phase 2 · registry result, not featured evidence · combination
23.3%30 mg intermittent
NCT00062751 · Phase 2 · registry result, not featured evidence · combination
33.3%25 mg daily
NCT00062751 · Phase 2 · registry result, not featured evidence · combination
12.1%10 mg daily
NCT00062751 · Phase 2 · registry result, not featured evidence · combination
Serious AEs
6.8%i
NCT01176916 · Phase 4 · registry result, not featured evidence
show 40 more results
44.9%Everolimus + Exemestane
NCT01743560 · Phase 4 · registry result, not featured evidence · combination
—Everolimus and Exemestane
NCT01743560 · Phase 4 · registry result, not featured evidence · combination
15.6%
NCT00253422 · Phase 3 · registry result, not featured evidence
22.7%
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
—Asian Everolimus + Exemestane
NCT03176238 · Phase 3 · registry result, not featured evidence · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
—Non-Asian Everolimus + Exemestane
NCT03176238 · Phase 3 · registry result, not featured evidence · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
1.7%
NCT00083174 · Phase 3 · registry result, not featured evidence
17.1%
NCT00036270 · Phase 3 · registry result, not featured evidence
30%Cohort 1 (Pembrolizumab, Doxorubic
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
10%Cohort 2 (Pembrolizumab, Anti-estr
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
43.9%
NCT02258451 · Phase 2 · registry result, not featured evidence · combination
11.1%
NCT00810797 · Phase 2 · registry result, not featured evidence
26.9%Abiraterone Acetate + Exemestane +
NCT01381874 · Phase 2 · registry result, not featured evidence · combination
20.7%Abiraterone Acetate + Prednisone
NCT01381874 · Phase 2 · registry result, not featured evidence · combination
16.7%5 mg + Exemestane
NCT02049957 · Phase 2 · registry result, not featured evidence · combination
33.3%4 mg + Exemestane
NCT02049957 · Phase 2 · registry result, not featured evidence · combination
14.3%4 mg + Exemestane
NCT02049957 · Phase 2 · registry result, not featured evidence · combination
25.6%4 mg + Exemestane
NCT02049957 · Phase 2 · registry result, not featured evidence · combination
0%3 mg + Exemestane
NCT02049957 · Phase 2 · registry result, not featured evidence · combination
—
NCT00201864 · Phase 2 · registry result, not featured evidence · combination
27.8%
NCT00767520 · Phase 2 · registry result, not featured evidence · combination
0%
NCT00073073 · Phase 2 · registry result, not featured evidence
25%
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
100%125mg
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
83.3%100mg
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
87.5%100mg
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
41.7%80mg bd 1w/1w + Ex 25mg
NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination
11.1%80mg bd 2w/1w + Ex 25mg
NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination
40%80mg bd Cont + Ex 25mg
NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination
—40mg Cont + Ex 25mg
NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination
40%40mg bd Cont + Ex 25mg
NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination
20%Part B: AZD4547 + Fulvestrant
NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination
0%DOSE FINDING PHASE, Arm A, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
25%DOSE FINDING PHASE, Arm A, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
57.1%DOSE FINDING PHASE, Arm B, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
50%Dose Finding Phase, Arm C, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
33.3%Dose Finding Phase, Arm C, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
0%Dose Finding Phase, Arm D, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
16.7%Dose Finding Phase, Arm D, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
28.6%Dose Finding Phase, Arm D, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
0%Fixed Dose Letrozolej
NCT01035099 · Phase 4 · registry result, not featured evidence
show 47 more results
0%Titrated Dose Letrozole
NCT01035099 · Phase 4 · registry result, not featured evidence
29.6%Palbociclib+Letrozole Australia Co
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
18%Palbociclib+Letrozole India Cohort
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
28.7%
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
—
NCT02941926 · Phase 3 · registry result, not featured evidence · combination
30.4%Ribociclib + Letrozole Cohort A
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
27.3%Ribociclib + Letrozole Cohort B
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
19.2%Ribociclib + Letrozole Cohort B1
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
28.7%Ribociclib + Letrozole Cohort B2
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
24.6%
NCT02600923 · Phase 3 · registry result, not featured evidence · combination
—
NCT00754845 · Phase 3 · registry result, not featured evidence
38%
NCT03633331 · Phase 2 · registry result, not featured evidence · combination
—Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
29.1%Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
0%Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort B: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
38.1%Cohort B: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
30.2%Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
30%Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—600 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
19.7%600mg
NCT03822468 · Phase 2 · registry result, not featured evidence
—400 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
20.2%400mg
NCT03822468 · Phase 2 · registry result, not featured evidence
30%Cohort 1 (Pembrolizumab, Doxorubic
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
10%Cohort 2 (Pembrolizumab, Anti-estr
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
—600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
15.2%600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
54.2%
NCT03644186 · Phase 2 · registry result, not featured evidence · combination
27.8%
NCT03007979 · Phase 2 · registry result, not featured evidence · combination
4%
NCT00530868 · Phase 2 · registry result, not featured evidence · combination
9.5%125 mg + 2.5 mg
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
33.3%125 mg + 2.5 mg
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
0%2.5 mg daily
NCT00579826 · Phase 2 · registry result, not featured evidence
—Letrozole
NCT00579826 · Phase 2 · registry result, not featured evidence
36.1%
NCT01231659 · Phase 2 · registry result, not featured evidence · combination
24.6%
NCT00696072 · Phase 2 · registry result, not featured evidence · combination
3%
NCT00090857 · Phase 2 · registry result, not featured evidence
3.8%
NCT00867217 · Phase 2 · registry result, not featured evidence
0%
NCT01129622 · Phase 2 · registry result, not featured evidence
14.3%50 mg with letrozole
NCT00708214 · Phase 2 · registry result, not featured evidence · combination
23.1%40 mg with letrozole
NCT00708214 · Phase 2 · registry result, not featured evidence · combination
62.5%30 mg with letrozole
NCT00708214 · Phase 2 · registry result, not featured evidence · combination
16.7%75 mg intermittent
NCT00062751 · Phase 2 · registry result, not featured evidence · combination
33.3%30 mg intermittent
NCT00062751 · Phase 2 · registry result, not featured evidence · combination
33.3%25 mg daily
NCT00062751 · Phase 2 · registry result, not featured evidence · combination
36.4%10 mg daily
NCT00062751 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs
i
arthralgia 9%
vaginal haemorrhage 5.9%
NCT01176916 · Phase 4 · registry result, not featured evidence
show 35 more results
diarrhoea 44.9%
fatigue 44.9%
cough 36.7%
NCT01743560 · Phase 4 · registry result, not featured evidence · combination
lethargy 56.1%
arthralgia 46.4%
vomiting 38.4%
NCT00253422 · Phase 3 · registry result, not featured evidence
neutrophil count decreased 62.7%
fatigue 55.3%
hypertension 34%
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
hot flashes 40.2% (placebo 31.9%)
pain joint 29.7% (placebo 27%)
fatigue 23.4% (placebo 20.7%)
NCT00083174 · Phase 3 · registry result, not featured evidence
hot flush 31.3%
arthralgia 23.8%
fatigue 16.4%
NCT00036270 · Phase 3 · registry result, not featured evidence
fatigue 90%
nausea 90%
white blood cell decreased 90%
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
fatigue 75%
alkaline phosphatase increased 50%
aspartate aminotransferase increased 45%
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
stomatitis 47.5% (placebo 49.6%)
anaemia 39.6% (placebo 28.8%)
decreased appetite 34.5% (placebo 25.2%)
NCT02258451 · Phase 2 · registry result, not featured evidence · combination
hot flashes 66.7%
blood glucose increased 61.1%
aspartate aminotransferase increased 58.3%
NCT00810797 · Phase 2 · registry result, not featured evidence
nausea 21.2%
fatigue 20.2%
vomiting 18.3%
NCT01381874 · Phase 2 · registry result, not featured evidence · combination
fatigue 27.6%
nausea 24.1%
hypokalaemia 21.8%
NCT01381874 · Phase 2 · registry result, not featured evidence · combination
5 mg + Exemestane
nausea 100%
stomatitis 83.3%
fatigue 66.7%
NCT02049957 · Phase 2 · registry result, not featured evidence · combination
4 mg + Exemestane
diarrhoea 66.7%
fatigue 66.7%
nausea 50%
NCT02049957 · Phase 2 · registry result, not featured evidence · combination
4 mg + Exemestane
fatigue 45.7%
hyperglycaemia 45.7%
nausea 42.9%
NCT02049957 · Phase 2 · registry result, not featured evidence · combination
4 mg + Exemestane
nausea 53.5%
fatigue 44.2%
diarrhoea 39.5%
NCT02049957 · Phase 2 · registry result, not featured evidence · combination
3 mg + Exemestane
dyspepsia 100%
abdominal pain 66.7%
arthralgia 66.7%
NCT02049957 · Phase 2 · registry result, not featured evidence · combination
nausea 36.7% (placebo 30.3%)
diarrhoea 31.6% (placebo 9.2%)
asthenia 26.6% (placebo 10.5%)
NCT00767520 · Phase 2 · registry result, not featured evidence · combination
hot flashes 33.3%
arthralgia 31%
fatigue 11.9%
NCT00073073 · Phase 2 · registry result, not featured evidence
cough 25%
dizziness 25%
dyspnoea 25%
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
125mg
mucositis oral 100%
neutrophil count decreased 100%
platelet count decreased 100%
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
100mg
mucositis oral 100%
neutrophil count decreased 83.3%
fatigue 50%
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
100mg
mucositis oral 96.9%
neutrophil count decreased 87.5%
fatigue 65.6%
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
80mg bd 1w/1w + Ex 25mg
dry mouth 58.3% (placebo 0%)
alopecia 50% (placebo 0%)
dysgeusia 50% (placebo 0%)
NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination
80mg bd 2w/1w + Ex 25mg
dysgeusia 66.7% (placebo 0%)
alopecia 55.6% (placebo 0%)
dry mouth 55.6% (placebo 0%)
NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination
80mg bd Cont + Ex 25mg
alopecia 100% (placebo 0%)
dry mouth 80% (placebo 0%)
diarrhoea 60% (placebo 0%)
NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination
40mg bd Cont + Ex 25mg
constipation 80% (placebo 0%)
alopecia 60% (placebo 0%)
dry mouth 60% (placebo 0%)
NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination
dry mouth 80% (placebo 0%)
alopecia 40% (placebo 0%)
asthenia 40% (placebo 0%)
NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination
rash maculo-papular 33.3%
abdominal pain 0%
alanine aminotransferase increased 0%
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
rash maculo-papular 50%
abdominal pain 25%
alkaline phosphatase increased 25%
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
aspartate aminotransferase increased 28.6%
abdominal pain 14.3%
blood bilirubin increased 14.3%
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
rash maculo-papular 33.3%
confusion 16.7%
lymphocyte count decreased 16.7%
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
lymphocyte count decreased 33.3%
rash maculo-papular 33.3%
anemia 16.7%
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
abdominal pain 0%
alanine aminotransferase increased 0%
alkaline phosphatase increased 0%
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
aspartate aminotransferase increased 33.3%
rash maculo-papular 33.3%
alkaline phosphatase increased 16.7%
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
lymphocyte count decreased 42.9%
neutrophil count decreased 42.9%
white blood cell decreased 42.9%
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
j
abdominal pain 18.2%
ohss 4.5%
NCT01035099 · Phase 4 · registry result, not featured evidence
show 38 more results
abdominal pain 33.3%
ohss 11.1%
NCT01035099 · Phase 4 · registry result, not featured evidence
neutropenia 72.4%
fatigue 65.1%
nausea 37.5%
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
neutropenia 57%
anaemia 22%
alopecia 17%
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
arthralgia 70.3%
hypertension 59%
proteinuria 47.7%
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
neutropenia 50.8%
nausea 40.8%
fatigue 38.6%
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
neutropenia 48.1%
nausea 42.1%
fatigue 40.4%
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
fatigue 57.7%
neutropenia 57.7%
hot flush 42.3%
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
neutropenia 46.5%
nausea 43.3%
fatigue 37.6%
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
neutropenia 70%
leukopenia 34.6%
anaemia 33.8%
NCT02600923 · Phase 3 · registry result, not featured evidence · combination
neutrophil count decreased 92.4%
white blood cell decreased 87%
fatigue 84.8%
NCT03633331 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 64.6%
hyperglycaemia 59.8%
nausea 46.5%
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
asthenia 100%
blood creatinine increased 100%
diarrhoea 100%
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 68.3%
hyperglycaemia 64.3%
nausea 54%
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
hyperglycaemia 67.5%
diarrhoea 54%
nausea 40.5%
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 70%
hyperglycaemia 60%
fatigue 50%
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
600mg
neutropenia 66.5%
leukopenia 27.7%
anaemia 26.1%
NCT03822468 · Phase 2 · registry result, not featured evidence
400mg
neutropenia 53.2%
alanine aminotransferase increased 26.1%
aspartate aminotransferase increased 21.8%
NCT03822468 · Phase 2 · registry result, not featured evidence
fatigue 90%
nausea 90%
white blood cell decreased 90%
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
fatigue 75%
alkaline phosphatase increased 50%
aspartate aminotransferase increased 45%
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
600 mg
neutropenia 65.2%
anaemia 35.7%
leukopenia 25.9%
NCT03839823 · Phase 2 · registry result, not featured evidence
diarrhea 65.3%
anemia 48.6%
platelet count decreased 38.9%
NCT03644186 · Phase 2 · registry result, not featured evidence · combination
white blood cell count decreased 96.3%
neutrophil count decreased 87%
anemia 79.6%
NCT03007979 · Phase 2 · registry result, not featured evidence · combination
headache 4%
NCT00530868 · Phase 2 · registry result, not featured evidence · combination
125 mg + 2.5 mg
neutrophil count decreased 81%
stomatitis 76.2%
white blood cell count decreased 71.4%
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
125 mg + 2.5 mg
neutrophil count decreased 100%
white blood cell count decreased 100%
diarrhoea 66.7%
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
2.5 mg daily
musculoskeletal pain 17.2% (placebo 11.5%)
atrial tachycardia 3.4% (placebo 0%)
cataract 3.4% (placebo 0%)
NCT00579826 · Phase 2 · registry result, not featured evidence
fatigue 68.1%
stomatitis 37.5%
decreased appetite 33.3%
NCT01231659 · Phase 2 · registry result, not featured evidence · combination
fatigue 50.9%
nausea 45.6%
pain 33.3%
NCT00696072 · Phase 2 · registry result, not featured evidence · combination
pain - muscle 6.1% (placebo 6.3%)
arthritis (non-septic) 3% (placebo 0%)
dizziness 3% (placebo 0%)
NCT00090857 · Phase 2 · registry result, not featured evidence
joint function 12.5% (placebo 11.3%)
arthralgia 8.8% (placebo 5%)
fatigue 7.5% (placebo 11.3%)
NCT00867217 · Phase 2 · registry result, not featured evidence
arthralgia 14.3%
headache 7.1%
NCT01129622 · Phase 2 · registry result, not featured evidence
50 mg with letrozole
diarrhoea 100%
acne 71.4%
mucosal inflammation 71.4%
NCT00708214 · Phase 2 · registry result, not featured evidence · combination
40 mg with letrozole
diarrhoea 92.3%
asthenia 61.5%
dermatitis acneiform 38.5%
NCT00708214 · Phase 2 · registry result, not featured evidence · combination
30 mg with letrozole
diarrhoea 87.5%
rash 75%
asthenia 50%
NCT00708214 · Phase 2 · registry result, not featured evidence · combination
75 mg intermittent
asthenia 100%
mucositis 66.7%
dry mouth 50%
NCT00062751 · Phase 2 · registry result, not featured evidence · combination
30 mg intermittent
asthenia 70%
diarrhea 50%
mucositis 50%
NCT00062751 · Phase 2 · registry result, not featured evidence · combination
25 mg daily
anemia 83.3%
asthenia 83.3%
arthralgia 66.7%
NCT00062751 · Phase 2 · registry result, not featured evidence · combination
10 mg daily
peripheral edema 48.5%
asthenia 45.5%
diarrhea 39.4%
NCT00062751 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aTrial phases differ: Phase 2 versus Phase 3.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dThe assessment timepoint is not available for both results.
  5. eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  6. fPopulation context differs: eligible sex differs (ALL versus FEMALE).
  7. gTrial phases differ: Phase 3 versus Phase 4.
  8. hTrial phases differ: Phase 3 versus Phase 2.
  9. iPopulation comparability has not been reviewed for 39 of these studies.
  10. jPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Exemestane

Disease-free Survival NA months
time to event · months
No placebo or comparator arm
NCT01176916 · Phase 4 · registry result, not featured evidence
Complete 0% (n=49) @ 48wk
responder rate · % of participants
No placebo or comparator arm
Best at WK 48 - Complete Response (CR)
NCT01743560 · Phase 4 · registry result, not featured evidence · combination · converted to % from 0 participants as posted
Partial 14.3% (n=49) @ 48wk
responder rate · % of participants
No placebo or comparator arm
Best at WK 48 - Partial Response (PR)
NCT01743560 · Phase 4 · registry result, not featured evidence · combination · converted to % from 7 participants as posted
Stable Disease 36.7% (n=49) @ 48wk
event count · % of participants
No placebo or comparator arm
Best at WK 48 - Stable Disease (SD)
NCT01743560 · Phase 4 · registry result, not featured evidence · combination · converted to % from 18 participants as posted
Progressive Disease 30.6% (n=49) @ 48wk
event count · % of participants
No placebo or comparator arm
Best at WK 48 - Progressive Disease (PD)
NCT01743560 · Phase 4 · registry result, not featured evidence · combination · converted to % from 15 participants as posted
Overall Survival Event 8 count
event count · count
No placebo or comparator arm
Deaths
NCT01743560 · Phase 4 · registry result, not featured evidence · combination
Duration of Clinical Benefit 12.2 months
time to event · months
No placebo or comparator arm
NCT00253422 · Phase 3 · registry result, not featured evidence
ORR 22.8% (n=206) vs 29.4% (n=187) Capecitabine
event count · % of participants
NCT02028507 · Phase 3 · registry result, not featured evidence · combination · converted to % from 47 Participants as posted
Clinical Benefit 76.2% (n=206) vs 82.4% (n=187) Capecitabine
event count · % of participants
NCT02028507 · Phase 3 · registry result, not featured evidence · combination · converted to % from 157 Participants as posted
Duration of Response 9.7 vs 11.2 Capecitabine months
time to event · months
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
show 2 more results
4.86 vs 6.47 Exemestane months @ 104wk
NCT01381874 · Phase 2 · registry result, not featured evidence · combination
6.93 vs 6.47 Exemestane months @ 104wk
NCT01381874 · Phase 2 · registry result, not featured evidence · combination
EORTC QLQ-C30 Global Health Status 3.28 vs 1.97 Capecitabine score
absolute change · score
Global health status / QoL
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
EORTC QLQ-C30 Physical Functioning -1.73 vs -2.94 Capecitabine score
absolute change · score
Physical functioning
NCT02028507 · Phase 3 · registry result, not featured evidence · combination

+ 42 further endpoints in the CSV export.

Letrozole

Mature Oocyte Yield 5.1 oocytes
absolute value · oocytes
No placebo or comparator arm
NCT01035099 · Phase 4 · registry result, not featured evidence
show 1 more result
7.9 oocytes
NCT01035099 · Phase 4 · registry result, not featured evidence
Mature Oocyte 0.29% (n=18)
responder rate · % of participants
No placebo or comparator arm
NCT01035099 · Phase 4 · registry result, not featured evidence
show 1 more result
0.46% (n=21)
NCT01035099 · Phase 4 · registry result, not featured evidence
Total Oocyte 17.1 oocytes
event count · oocytes
No placebo or comparator arm
NCT01035099 · Phase 4 · registry result, not featured evidence
show 1 more result
19 oocytes
NCT01035099 · Phase 4 · registry result, not featured evidence
Fertilized Oocyte 3.7 fertlized oocytes
event count · fertlized oocytes
No placebo or comparator arm
NCT01035099 · Phase 4 · registry result, not featured evidence
show 1 more result
5.3 fertlized oocytes
NCT01035099 · Phase 4 · registry result, not featured evidence
Complete 1% (n=100)
responder rate · % of participants
No placebo or comparator arm
Percentage of participants with complete response
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
1.3% (n=152)
Percentage of participants with complete response
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
Partial 28% (n=100)
responder rate · % of participants
No placebo or comparator arm
Percentage of participants with partial response
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
11.8% (n=152)
Percentage of participants with partial response
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
ORR 29% (n=100)
absolute value · percentage points
No placebo or comparator arm
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
show 3 more results
13.2% (n=152)
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
24.8% (n=129)
NCT02600923 · Phase 3 · registry result, not featured evidence · combination
55% (n=47)
NCT03633331 · Phase 2 · registry result, not featured evidence · combination
EQ-5D Utility 0.698 score
absolute value · score
No placebo or comparator arm
End of Treatment (EOT)
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
EQ-5D Utility -0.147 score
absolute change · score
No placebo or comparator arm
End of Treatment (EOT)
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
EQ-5D-VAS 73.6 score
absolute value · score
No placebo or comparator arm
End of Treatment (EOT)
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
EQ-5D VAS -3.2 score
absolute change · score
No placebo or comparator arm
End of Treatment (EOT)
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
PFS-12 73% (n=173) vs 61% (n=170) Endocrine Therapy @ 52wk
responder rate · % of participants
NCT00601900 · Phase 3 · registry result, not featured evidence · combination

+ 67 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Exemestane's landscape · Letrozole's landscape